Here are four things to know about the market.
- It’s projected to reach $4.6 billion by 2025.
- This market growth is attributed to growing awareness of genomic tests and increasing availability of direct-to-consumer products.
- Its key market players include BGI, Illumina, Pathway Genomics, Genesis Genetics and 23andMe.
- The largest share of predictive testing is attributed to breast and ovarian cancer. Looking forward, genetic tests related to gynecology and endocrinology have generated interest.
Click here to view the full report.
More articles on health IT:
UW Health partners with American Well
‘Focus on the basics’: 3 questions with Eligible founder Katelyn Gleason
How advanced analytics can integrate mental health as routine patient care
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
